Literature DB >> 6354937

Mood changes during captopril therapy for hypertension. A double-blind pilot study.

J S Callender, G P Hodsman, M J Hutcheson, A F Lever, J I Robertson.   

Abstract

A small double-blind pilot study was carried out to assess whether captopril treatment in hypertension has a euphoriant effect. Eight patients were maintained on constant therapy of atenolol and bendrofluazide for at least 4 weeks before and throughout the study. Captopril 25 mg three times daily or matching placebo was administered double-blind for 6 weeks, with crossover to placebo or captopril from Weeks 7 to 12. Psychiatric assessment was made at Weeks 3, 6, 9, and 12. During the captopril phase, blood pressure was reduced, plasma angiotensin II lowered, and plasma renin raised. Mood was slightly, but significantly, lower during captopril administration; thus, there was no evidence of an euphoriant effect of captopril. This pilot trial also indicates the feasibility of the approach, and such studies of hypertensives under therapy should be usefully extended and refined.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6354937     DOI: 10.1161/01.hyp.5.5_pt_2.iii90

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  5 in total

Review 1.  Antihypertensive medications and depression.

Authors:  M H Beers; L J Passman
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

Review 2.  Evaluation of mood and the effect of angiotensin-converting enzyme inhibitors.

Authors:  S Jern
Journal:  Drugs       Date:  1988       Impact factor: 9.546

Review 3.  Angiotensin converting enzyme inhibitors and moderate hypertension.

Authors:  D McAreavey; J I Robertson
Journal:  Drugs       Date:  1990-09       Impact factor: 9.546

Review 4.  The effect of antihypertensive treatment on the quality of later years.

Authors:  M A James; J F Potter
Journal:  Drugs Aging       Date:  1993 Jan-Feb       Impact factor: 3.923

Review 5.  The renin-angiotensin system: a possible new target for depression.

Authors:  João Vian; Círia Pereira; Victor Chavarria; Cristiano Köhler; Brendon Stubbs; João Quevedo; Sung-Wan Kim; André F Carvalho; Michael Berk; Brisa S Fernandes
Journal:  BMC Med       Date:  2017-08-01       Impact factor: 8.775

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.